Objective<\/strong>: We aimed to evaluate results of telaprevir, pegylated interferon and ribavirin treatment of patients with hepatitis C virus (HCV) genotype 1b infection.<\/p>\n Methods<\/strong>: We evaluated results of telaprevir-based triple therapy in treatment-experienced 53 chronic hepatitis C (CHC) patients followed in five hospitals in Gaziantep, retrospectively. Demographic data of patients, adverse events, treatment indications, sustained virologic response (SVR) rates and outcomes were recorded.<\/p>\n Results<\/strong>: 43 (81.1%) of 53 patients with HCV genotype 1 infection included in the study completed the treatment. Of patients treated, 44 (83%) had had a relapse and 9 (17%) were previous non-responders. Telaprevir-based triple therapy achieved SVR in 31 (58.5%) patients. Pruritus, rash, anemia and anorectal discomfort were main adverse effects. Blood transfusion and ribavirin dose reduction were required for 19 and 13 patients, respectively. Of patients, 10 (18.9%) discontinued therapy because of severe adverse effects.<\/p>\n Conclusions<\/strong>: Despite of more severe and frequent adverse effects, telaprevir-based therapy has provided SVR in more than a half of patients with CHC for both relapse and non-responder patient groups before an era of new direct acting antiviral agents.\u00a0<\/p>\n Klimik Dergisi 2017; 30(3): 126-30.<\/p>\n Cite this article as<\/strong>: \u015eahin A, Bayram H, Nam\u0131duru M, et al. [Evaluation of 53 cases with chronic hepatitis C receiving telaprevir-based triple therapy]. Klimik Derg. 2017; 30(3): 126-30. Turkish.<\/p>\n","protected":false},"excerpt":{"rendered":" Abstract Objective: We aimed to evaluate results of telaprevir, pegylated interferon and ribavirin treatment of patients with hepatitis C virus (HCV) genotype 1b infection. Methods: We evaluated results of telaprevir-based triple therapy in treatment-experienced 53 chronic hepatitis C (CHC) patients followed in five hospitals in Gaziantep, retrospectively. Demographic data of patients, adverse events, treatment indications, […]<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[5130],"tags":[4643,2789,4454],"class_list":["post-14940","post","type-post","status-publish","format-standard","hentry","category-original-article","tag-gaziantep","tag-hepatitis-c-virus","tag-telaprevir"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.klimikdergisi.org\/en\/wp-json\/wp\/v2\/posts\/14940","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.klimikdergisi.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.klimikdergisi.org\/en\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/www.klimikdergisi.org\/en\/wp-json\/wp\/v2\/comments?post=14940"}],"version-history":[{"count":0,"href":"https:\/\/www.klimikdergisi.org\/en\/wp-json\/wp\/v2\/posts\/14940\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.klimikdergisi.org\/en\/wp-json\/wp\/v2\/media?parent=14940"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.klimikdergisi.org\/en\/wp-json\/wp\/v2\/categories?post=14940"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.klimikdergisi.org\/en\/wp-json\/wp\/v2\/tags?post=14940"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}